ATE422352T1 - Liposomaler grippeimpfstoff und verfahren - Google Patents

Liposomaler grippeimpfstoff und verfahren

Info

Publication number
ATE422352T1
ATE422352T1 AT97927355T AT97927355T ATE422352T1 AT E422352 T1 ATE422352 T1 AT E422352T1 AT 97927355 T AT97927355 T AT 97927355T AT 97927355 T AT97927355 T AT 97927355T AT E422352 T1 ATE422352 T1 AT E422352T1
Authority
AT
Austria
Prior art keywords
methods
liposomal
flu vaccine
vaccines
influenza
Prior art date
Application number
AT97927355T
Other languages
English (en)
Inventor
Eliezer Kedar
Ilan Babai
Yechezkel Barenholz
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE422352T1 publication Critical patent/ATE422352T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97927355T 1996-06-24 1997-06-24 Liposomaler grippeimpfstoff und verfahren ATE422352T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2006396P 1996-06-24 1996-06-24

Publications (1)

Publication Number Publication Date
ATE422352T1 true ATE422352T1 (de) 2009-02-15

Family

ID=21796541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927355T ATE422352T1 (de) 1996-06-24 1997-06-24 Liposomaler grippeimpfstoff und verfahren

Country Status (8)

Country Link
US (1) US5919480A (de)
EP (1) EP0954286B1 (de)
JP (2) JP4227195B2 (de)
AT (1) ATE422352T1 (de)
AU (1) AU731705B2 (de)
CA (1) CA2258878C (de)
DE (1) DE69739253D1 (de)
WO (1) WO1997049423A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731972B1 (en) * 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
AU1208499A (en) * 1997-10-31 1999-05-24 Cistron Biotechnology, Inc. Encapsulated immunomodulators useful as vaccine adjuvants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
WO2002038175A1 (en) 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AU2002236526B9 (en) * 2000-11-15 2008-05-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sol-fusin: use of GP64-6His to catalyze membrane fusion
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
EP1401492B1 (de) * 2001-07-05 2009-05-20 LTB4 Sweden AB Ltb4 als adjuvans für impfstoffe
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
EP1528915A2 (de) * 2002-07-03 2005-05-11 Aphton Corporation Liposomaler impfstoff
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
EP1617808A4 (de) 2003-04-25 2011-11-02 Penn State Res Found Verfahren und system für die systemische abgabe von wachstumshemmenden von lipiden stammenden bioaktiven verbindungen
CA2524634A1 (en) * 2003-05-09 2004-11-25 Novosom Ag Injectable liposomal depots for delivering active ingredients
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
JP4970035B2 (ja) * 2003-08-21 2012-07-04 リポテック・プロプライエタリー・リミテッド ｉｎｖｉｖｏにおける樹状細胞の標的化
FR2868951B1 (fr) * 2004-04-15 2006-07-21 Ethypharm Sa Compositions contenant ds vesicules lamellaires incorporant un principe actif peu soluble dans l'eau et produits intermediaires utiles pour leur preparation
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
RU2007129840A (ru) * 2005-01-05 2009-02-20 Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) Средства доставки, биологически активные вещества и вирусные вакцины
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2231180B1 (de) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Impfstoff für die alzheimerkrankheit
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CA2730340C (en) 2008-07-14 2017-02-07 Polypid Ltd. Sustained-release drug carrier composition
WO2010086864A1 (en) 2009-02-02 2010-08-05 Galmed International Ltd. Methods and compositions for treating alzheimer's disease
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CN105126179B (zh) 2009-07-14 2018-09-25 波利皮得有限公司 持续释放药物载体组合物
AU2010303568B2 (en) 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
JP5860409B2 (ja) 2010-01-19 2016-02-16 ポリピッド リミテッド 徐放性核酸マトリックス組成物
WO2012006367A2 (en) * 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
IN2014CN02581A (de) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
CN103736090B (zh) * 2014-01-27 2016-03-02 中国医学科学院医学生物学研究所 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗
CN110151702A (zh) * 2019-06-24 2019-08-23 昆明医科大学 聚乙二醇修饰流感疫苗脂质体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
NZ230423A (en) * 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3037994B2 (ja) * 1989-11-02 2000-05-08 テルモ株式会社 リポソーム表面への蛋白質吸着抑制剤
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
CA2139756A1 (en) * 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
EP0713388B1 (de) * 1993-08-06 1999-05-06 Opperbas Holding B.V. Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity

Also Published As

Publication number Publication date
EP0954286B1 (de) 2009-02-11
JP2008260779A (ja) 2008-10-30
CA2258878C (en) 2008-03-18
US5919480A (en) 1999-07-06
WO1997049423A3 (en) 1998-02-19
JP2000513352A (ja) 2000-10-10
AU731705B2 (en) 2001-04-05
JP4227195B2 (ja) 2009-02-18
EP0954286A2 (de) 1999-11-10
CA2258878A1 (en) 1997-12-31
AU3188297A (en) 1998-01-14
DE69739253D1 (de) 2009-03-26
WO1997049423A2 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
ATE422352T1 (de) Liposomaler grippeimpfstoff und verfahren
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
EP1955709A3 (de) Adjuvanzverbindungen zur Verbesserung von Immunreaktionen auf Polynukleotid-basierten Impfstoffen
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
EP1964573A3 (de) Verfahren zur Induzierung und/oder Verbesserung einer Immunreaktion auf Tumorantigene
DE69533594D1 (de) Präparate und verfahren zum auslösen von ctl-immunität
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
FI953608L (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella
BG101995A (en) Saponin and sterol-containing vaccines
EP2368575A3 (de) Trockenformulierung für transkutane immunisierung
DE68921389D1 (de) Influenzaimpfstoff und Adjuvanten.
WO1999002183A3 (en) A method of inducing a ctl response
EP0705109A4 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
EP1162272A3 (de) Herstellung von einer Immunantwort gegen Prostat-spezifisches Antigen (SPA)
BR9506885A (pt) Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
DK0792165T3 (da) Immunogene præparater
WO2002076485A3 (en) Vaccine for modulating between t1 and t2 immune responses
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
DE69433760D1 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
EP0320034A3 (de) Synthetische Peptide, die immunologische Aktivität zeigen, benutzbar, um eine Impfung gegen Malaria vorzubereiten
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.
IT8821666A0 (it) Coniugato peptidico immunologicamente attivo utile come vaccino antimalaria e metodo di immunizzazione impiegante lo stesso
EP1852126A3 (de) Impfstoff zur Modulation zwischen T1 und T2 Immunantworten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties